For research use only. Not for therapeutic Use.
CNX-011-67 is a highly potent and selective small molecule agonist with an EC50 of 0.24 nM towards human GPR40. CNX-011-67 suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro. CNX-011-67 enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
| Catalog Number | I006184 |
| Synonyms | CNX-011-67; CNX011-67; CNX 011-67; CNX-01167; CNX01167; CNX 01167.;unknow. |
| Purity | ≥95% |
| Target | GPR40 agonist |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| Reference | </br>1:A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro. Verma MK, Biswas S, Chandravanshi B, Neelima K, Oommen AM, Jagannath MR, Somesh BP.BMC Res Notes. 2014 Sep 3;7:595. doi: 10.1186/1756-0500-7-595. PMID: 25186493 Free PMC Article</br>2:CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. Sunil V, Verma MK, Oommen AM, Sadasivuni M, Singh J, Vijayraghav DN, Chandravanshi B, Shetty J, Biswas S, Dandu A, Moolemath Y, Venkataranganna MV, Somesh BP, Jagannath MR.BMC Pharmacol Toxicol. 2014 Mar 25;15:19. doi: 10.1186/2050-6511-15-19. PMID: 24666736 Free PMC Article</br>3:Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR.BMC Pharmacol Toxicol. 2013 May 21;14:28. doi: 10.1186/2050-6511-14-28. PMID: 23692921 Free PMC Article |
